Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/NBIX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Neurocrine Biosciences Inc (NBIX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with neutral technical signals. The company demonstrates strong fundamentals with 2025 revenue of $2.86B, net income margin of 20.91%, and consistent earnings beats. Recent news highlights institutional buying interest and product pipeline advancements, though safety concerns for Vykat XR caused temporary volatility. Analyst consensus remains strongly bullish with 86% buy ratings and $207.07 price target.
NBIX presents a compelling growth story with robust profitability and expanding rare-disease portfolio, though execution risks and premium valuation require monitoring. The stock offers significant upside to analyst targets but faces headwinds from competitive pressures and drug safety scrutiny. Current levels provide entry opportunity for long-term investors comfortable with biopharma volatility.
Read full analysis

Key Stats

  • Market Cap
    $15.77B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $185.50
  • 52W Low
    $123.10
  • Typical Hold Time
    -
  • Enterprise Value
    $15.78B
  • Div Yield
    -
  • Trading Activity
    -
$154
52W Low: $123.1
12 Feb 2026
52W High: $185.5
30 Jul 2026

Track Neurocrine Biosciences Inc (NBIX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $123.1 and a high of $185.5, highlighting its annual price range. Buy and sell Neurocrine Biosciences Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Most Recent News

Content is generated by Aura AI

CoreWeave CEO says AI firms haven't clearly explained benefits of data centers to the public

At the Goldman Sachs Communcacopia + Technology conference, CoreWeave CEO Mike Intrator criticized AI companies for not effectively communicating the benefits of data centers that support AI technology. He emphasized that public fear is less about da...

Market News
4 hours ago
CNBC
Neutral
CoreWeave CEO says AI firms haven't clearly explained benefits of data centers to the public

Fed meeting looms over Amazon and Oracle's costly AI cloud expansions amid negative cash flow.

Amazon and Oracle reported record cloud backlogs but are facing negative free cash flow due to massive investments in AI data centers. Oracle plans $70 billion in capital expenditures for FY2027, funded by $40 billion in new debt and equity, while Am...

Market News
4 hours ago
24/7 Wall Street
Neutral
Fed meeting looms over Amazon and Oracle's costly AI cloud expansions amid negative cash flow.

AI investment splits Magnificent Seven; NVIDIA leads gains while hyperscalers lag behind S&P 500 in 2026.

Jim Cramer urges buying the Magnificent Seven stocks ahead of AI profits, but market strategist Lo Toney highlights a split: hyperscalers like Google, Microsoft, and Amazon investing heavily in AI infrastructure are trailing the S&P 500, while NVIDIA...

Market News
4 hours ago
24/7 Wall Street
Neutral
AI investment splits Magnificent Seven; NVIDIA leads gains while hyperscalers lag behind S&P 500 in 2026.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $15.77B
  • Volume
    -
  • Sector
    Health
  • 52W High
    $185.50
  • 52W Low
    $123.10
  • Typical Hold Time
    -
  • Enterprise Value
    $15.78B
  • Div Yield
    -
  • Trading Activity
    -
$154
52W Low: $123.1
12 Feb 2026
52W High: $185.5
30 Jul 2026

Track Neurocrine Biosciences Inc (NBIX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $123.1 and a high of $185.5, highlighting its annual price range. Buy and sell Neurocrine Biosciences Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!